606 related articles for article (PubMed ID: 19713488)
1. Nociceptin/orphanin FQ receptor activation attenuates antinociception induced by mixed nociceptin/orphanin FQ/mu-opioid receptor agonists.
Khroyan TV; Polgar WE; Jiang F; Zaveri NT; Toll L
J Pharmacol Exp Ther; 2009 Dec; 331(3):946-53. PubMed ID: 19713488
[TBL] [Abstract][Full Text] [Related]
2. Effects of spinally administered bifunctional nociceptin/orphanin FQ peptide receptor/μ-opioid receptor ligands in mouse models of neuropathic and inflammatory pain.
Sukhtankar DD; Zaveri NT; Husbands SM; Ko MC
J Pharmacol Exp Ther; 2013 Jul; 346(1):11-22. PubMed ID: 23652222
[TBL] [Abstract][Full Text] [Related]
3. Roles of μ-opioid receptors and nociceptin/orphanin FQ peptide receptors in buprenorphine-induced physiological responses in primates.
Cremeans CM; Gruley E; Kyle DJ; Ko MC
J Pharmacol Exp Ther; 2012 Oct; 343(1):72-81. PubMed ID: 22743574
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of nociceptin/orphanin FQ (NOP) receptor agonists in acute versus chronic pain: studies with bifunctional NOP/μ receptor agonists in the sciatic nerve ligation chronic pain model in mice.
Khroyan TV; Polgar WE; Orduna J; Montenegro J; Jiang F; Zaveri NT; Toll L
J Pharmacol Exp Ther; 2011 Nov; 339(2):687-93. PubMed ID: 21859931
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: in vitro studies.
Spagnolo B; Carrà G; Fantin M; Fischetti C; Hebbes C; McDonald J; Barnes TA; Rizzi A; Trapella C; Fanton G; Morari M; Lambert DG; Regoli D; Calò G
J Pharmacol Exp Ther; 2007 Jun; 321(3):961-7. PubMed ID: 17329552
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the antinociceptive and antirewarding profiles of novel bifunctional nociceptin receptor/mu-opioid receptor ligands: implications for therapeutic applications.
Toll L; Khroyan TV; Polgar WE; Jiang F; Olsen C; Zaveri NT
J Pharmacol Exp Ther; 2009 Dec; 331(3):954-64. PubMed ID: 19773529
[TBL] [Abstract][Full Text] [Related]
7. The biology of Nociceptin/Orphanin FQ (N/OFQ) related to obesity, stress, anxiety, mood, and drug dependence.
Witkin JM; Statnick MA; Rorick-Kehn LM; Pintar JE; Ansonoff M; Chen Y; Tucker RC; Ciccocioppo R
Pharmacol Ther; 2014 Mar; 141(3):283-99. PubMed ID: 24189487
[TBL] [Abstract][Full Text] [Related]
8. SR 16435 [1-(1-(bicyclo[3.3.1]nonan-9-yl)piperidin-4-yl)indolin-2-one], a novel mixed nociceptin/orphanin FQ/mu-opioid receptor partial agonist: analgesic and rewarding properties in mice.
Khroyan TV; Zaveri NT; Polgar WE; Orduna J; Olsen C; Jiang F; Toll L
J Pharmacol Exp Ther; 2007 Feb; 320(2):934-43. PubMed ID: 17132815
[TBL] [Abstract][Full Text] [Related]
9. Buprenorphine-induced antinociception is mediated by mu-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors.
Lutfy K; Eitan S; Bryant CD; Yang YC; Saliminejad N; Walwyn W; Kieffer BL; Takeshima H; Carroll FI; Maidment NT; Evans CJ
J Neurosci; 2003 Nov; 23(32):10331-7. PubMed ID: 14614092
[TBL] [Abstract][Full Text] [Related]
10. The first universal opioid ligand, (2S)-2-[(5R,6R,7R,14S)-N-cyclopropylmethyl-4,5-epoxy-6,14-ethano-3-hydroxy-6-methoxymorphinan-7-yl]-3,3-dimethylpentan-2-ol (BU08028): characterization of the in vitro profile and in vivo behavioral effects in mouse models of acute pain and cocaine-induced reward.
Khroyan TV; Polgar WE; Cami-Kobeci G; Husbands SM; Zaveri NT; Toll L
J Pharmacol Exp Ther; 2011 Mar; 336(3):952-61. PubMed ID: 21177476
[TBL] [Abstract][Full Text] [Related]
11. Buprenorphine requires concomitant activation of NOP and MOP receptors to reduce cocaine consumption.
Kallupi M; Shen Q; de Guglielmo G; Yasuda D; Journigan VB; Zaveri NT; Ciccocioppo R
Addict Biol; 2018 Mar; 23(2):585-595. PubMed ID: 28635181
[TBL] [Abstract][Full Text] [Related]
12. Cebranopadol: a novel potent analgesic nociceptin/orphanin FQ peptide and opioid receptor agonist.
Linz K; Christoph T; Tzschentke TM; Koch T; Schiene K; Gautrois M; Schröder W; Kögel BY; Beier H; Englberger W; Schunk S; De Vry J; Jahnel U; Frosch S
J Pharmacol Exp Ther; 2014 Jun; 349(3):535-48. PubMed ID: 24713140
[TBL] [Abstract][Full Text] [Related]
13. Activities of mixed NOP and mu-opioid receptor ligands.
Spagnolo B; Calo G; Polgar WE; Jiang F; Olsen CM; Berzetei-Gurske I; Khroyan TV; Husbands SM; Lewis JW; Toll L; Zaveri NT
Br J Pharmacol; 2008 Feb; 153(3):609-19. PubMed ID: 18059322
[TBL] [Abstract][Full Text] [Related]
14. Quantitative study of the antagonistic effect of (-)-cis-1-Methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol (SB-612111) on nociceptin/orphanin FQ-mediated potassium channel activation in rat periaqueductal gray slices.
Liao YY; Jiang F; Chiou LC
Eur J Pharmacol; 2011 Apr; 657(1-3):84-8. PubMed ID: 21300055
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: in vivo studies.
Rizzi A; Gavioli EC; Marzola G; Spagnolo B; Zucchini S; Ciccocioppo R; Trapella C; Regoli D; Calò G
J Pharmacol Exp Ther; 2007 Jun; 321(3):968-74. PubMed ID: 17329551
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo pharmacological characterization of J-113397, a potent and selective non-peptidyl ORL1 receptor antagonist.
Ozaki S; Kawamoto H; Itoh Y; Miyaji M; Azuma T; Ichikawa D; Nambu H; Iguchi T; Iwasawa Y; Ohta H
Eur J Pharmacol; 2000 Aug; 402(1-2):45-53. PubMed ID: 10940356
[TBL] [Abstract][Full Text] [Related]
17. Discovery of the first small-molecule opioid pan antagonist with nanomolar affinity at mu, delta, kappa, and nociceptin opioid receptors.
Zaveri NT; Journigan VB; Polgar WE
ACS Chem Neurosci; 2015 Apr; 6(4):646-57. PubMed ID: 25635572
[TBL] [Abstract][Full Text] [Related]
18. BPR1M97, a dual mu opioid receptor/nociceptin-orphanin FQ peptide receptor agonist, produces potent antinociceptive effects with safer properties than morphine.
Chao PK; Chang HF; Chang WT; Yeh TK; Ou LC; Chuang JY; Tsu-An Hsu J; Tao PL; Loh HH; Shih C; Ueng SH; Yeh SH
Neuropharmacology; 2020 Apr; 166():107678. PubMed ID: 31278929
[TBL] [Abstract][Full Text] [Related]
19. Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP-receptor selective scaffolds. Part II.
Journigan VB; Polgar WE; Khroyan TV; Zaveri NT
Bioorg Med Chem; 2014 Apr; 22(8):2508-16. PubMed ID: 24657054
[TBL] [Abstract][Full Text] [Related]
20. BU08073 a buprenorphine analogue with partial agonist activity at μ-receptors in vitro but long-lasting opioid antagonist activity in vivo in mice.
Khroyan TV; Wu J; Polgar WE; Cami-Kobeci G; Fotaki N; Husbands SM; Toll L
Br J Pharmacol; 2015 Jan; 172(2):668-80. PubMed ID: 24903063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]